Awaiting development: Guidance and quality standards

Showing 31 to 40 of 326

Guidance and quality standards awaiting development
Title	Type
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]	Technology appraisal guidance
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor ID 6476	Technology appraisal guidance
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer ID6481	Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769	Technology appraisal guidance
Benralizumab for previously treated severe nasal polyps [ID1659]	Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]	Technology appraisal guidance
Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550	Technology appraisal guidance
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]	Technology appraisal guidance
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years TSID 12054	Technology appraisal guidance
BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]	Technology appraisal guidance